The global veterinary vaccines market size was valued at almost US$ 6,900 Mn in 2018 and is anticipated to reach over US$ 12,000 Mn by 2026, expanding at a CAGR of above 6.7% from 2019 to 2026. Rise in demand for preventing animal to human transmission of diseases and increase in the dependency on livestock animals for the growth of economy are likely to boost demand for veterinary vaccines during the forecast period. North America and Europe are likely to dominate the global veterinary vaccines market due to high spending on animal health care and rise in focus of key players on the development of new vaccines in the market in these regions. Increase in ownership of companion animals and rise in prevalence of animal to human transmission of diseases in countries such as Japan and China are likely to boost the veterinary vaccines market in Asia Pacific in the coming years.
The report analyzes and forecasts the veterinary vaccines market at global and regional levels. The market has been forecast based on volume (Tons) and value (US$ Mn) from 2019 to 2026. The study includes drivers and restraints of the global market. It covers the impact of these drivers and restraints on the demand during the forecast period. The report also highlights opportunities in the market at the global level. For the region and all segments, the sales, revenue and their market share, growth rate are key research objects; we can research the manufacturers' sales, price, revenue, cost and gross profit and their changes. What's more, we will display the main consumers, raw material manufacturers, distributors, etc.
This report first introduces the background of veterinary vaccines, including the definition, classification, application, industrial chain structure, industry overview, national policy and planning analysis of the industry, and the latest dynamic analysis. With regard to production bases and technologies, the research in this report covers the production time, base distribution, technical parameters, research and development trends, technology sources, and sources of raw materials of major veterinary vaccines companies.
Regarding the analysis of the industry chain, the research of this report covers the raw materials and equipment of veterinary vaccines upstream, downstream customers, marketing channels, industry development trends and investment strategy recommendations. The more specific analysis also includes the main application areas of veterinary vaccines and consumption, major regions and consumption, major global producers, distributors, raw material suppliers, equipment providers and their contact information, industry chain relationship analysis.
The report comprises a detailed value chain analysis, which provides a comprehensive view of the global veterinary vaccines market. The Porter’s Five Forces model has also been included to help understand the competitive landscape of the market. The study encompasses market attractiveness analysis, wherein various applications have been benchmarked based on their market size, growth rate, and general attractiveness.
The study provides a decisive view of the veterinary vaccines market by segmenting it in terms of form and application. The segment has been analyzed based on the present and future trends. Regional segmentation includes the current and projected demand in North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
The report provides size (in terms of volume and value) of veterinary vaccines market for the base year 2018 and the forecast between 2019 and 2026. Market numbers have been estimated based on form and application. Market size and forecast for each application segment have been provided for the global and regional market.
Companies Mentioned in Report
The report also profiles major players in the market in terms of various attributes such as company overview, financial overview, devices portfolios, business strategies, and recent developments. Major companies profiled in the global veterinary vaccines market include Boehringer Ingelheim GmbH, Merck Animal Health, Zoetis Inc., Eli Lilly and Company, Bayer AG (Bayer Animal Health), Ceva Santé Animale, Virbac, Biovac, Neogen Corporation, and ImmuCell Corporation.
The global veterinary vaccines market has been segmented as follows:
Global Veterinary Vaccines Market, by Technology
Global Veterinary Vaccines Market, by Animal
Global Veterinary Vaccines Market, by Region
Research Methodology:
In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report.
Primary research represents a bulk of research efforts, supplemented by extensive secondary research. Annual reports, press releases, and relevant documents of key players operating in various application areas have been reviewed for competition analysis and market understanding.
Secondary research also includes recent trends, technical writing, Internet sources, and statistical data from government websites, trade associations, and agencies. These have proved to be reliable, effective, and successful approaches for obtaining precise market data, capturing market participants’ insights, and recognizing business opportunities.
The study objectives of this report are:
Chapter 1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
Chapter 2. Assumptions and Research Methodology
Chapter 3. Executive Summary: Global Veterinary Vaccines Market
Chapter 4. Market Overview
4.1. Introduction
4.1.1. Product Overview
4.2. Market Dynamics
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.3. Global Veterinary Vaccines Market Analysis and Forecasts, 2018–2026
4.3.1. Market Revenue Projection (US$ Mn)
Chapter 5. Market Outlook
5.1. White Space Analysis
5.2. Disease Outbreak Globally : Livestock Animal Disease
5.3. Main (Vector Borne Disease) VBDs affecting livestock
5.4. Animal Population (Mn), by Key Country in 2019
5.5. Top Ten Countries with Highest Number of Vets and Vet Clinics, 2018
5.6. Pet Ownership (%) by Key Country, 2018
5.7. Key Merger & Acquisition in Animal Health Industry
5.8. Regulatory Scenario by Region
Chapter 6. Global Veterinary Vaccines Market Analysis and Forecasts, by Technology
6.1. Key Findings/Developments
6.2. Introduction & Definition
6.3. Market Value Forecast, by Technology, 2019–2026
6.3.1. Inactivated Vaccines
6.3.2. Conjugate Vaccines
6.3.3. Live Attenuated Vaccines
6.3.4. Toxoid Vaccines
6.3.5. Other Vaccines
6.4. Market Attractiveness, by Technology
Chapter 7. Global Veterinary Vaccines Market Analysis and Forecasts, by Animal
7.1. Key Findings/Developments
7.2. Introduction & Definition
7.3. Market Value Forecast, by Animal, 2019–2026
7.3.1. Livestock Animal Vaccines
7.3.2. Companion Animal Vaccines
7.4. Market Attractiveness, by Animal
Chapter 8. Global Veterinary Vaccines Market Analysis and Forecasts, by Region
8.1. Geographical Representation
8.2. Market Value Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia Pacific
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness, by Region
Chapter 9. North America Veterinary Vaccines Market Analysis and Forecast
9.1. Market Value Forecast, by Country, 2019–2026
9.1.1. U.S.
9.1.2. Canada
9.2. Market Value Share Analysis, by Technology, 2019–2026
9.3. Market Value Forecast, by Technology, 2018–2026
9.3.1. Inactivated Vaccines
9.3.2. Conjugate Vaccines
9.3.3. Live Attenuated Vaccines
9.3.4. Toxoid Vaccines
9.3.5. Other Vaccines
9.4. Market Value Share Analysis, by Animal, 2019–2026
9.5. Market Value Forecast, by Animal, 2018–2026
9.5.1. Livestock Animal Vaccines
9.5.2. Companion Animal Vaccines
9.6. Market Attractiveness Analysis
9.6.1. By Country
9.6.2. By Technology
9.6.3. By Animal
Chapter 10. Europe Veterinary Vaccines Market Analysis and Forecast
10.1. Market Value Forecast, by Country/Sub-region, 2019–2026
10.1.1. Germany
10.1.2. France
10.1.3. U.K.
10.1.4. Spain
10.1.5. Italy
10.1.6. Rest of Europe
10.2. Market Value Share Analysis, by Technology, 2019–2026
10.3. Market Value Forecast, by Technology, 2018–2026
10.3.1. Inactivated Vaccines
10.3.2. Conjugate Vaccines
10.3.3. Live Attenuated Vaccines
10.3.4. Toxoid Vaccines
10.3.5. Other Vaccines
10.4. Market Value Share Analysis, by Animal, 2019–2026
10.5. Market Value Forecast, by Animal, 2018–2026
10.5.1. Livestock Animal Vaccines
10.5.2. Companion Animal Vaccines
10.6. Market Attractiveness Analysis
10.6.1. By Country/Sub-region
10.6.2. By Technology
10.6.3. By Animal
Chapter 11. Asia Pacific Veterinary Vaccines Market Analysis and Forecast
11.1. Market Value Forecast, by Country/Sub-region, 2019–2026
11.1.1. China
11.1.2. Japan
11.1.3. India
11.1.4. Australia & New Zealand
11.1.5. Rest of Asia Pacific
11.2. Market Value Share Analysis, by Technology, 2019–2026
11.3. Market Value Forecast, by Technology, 2018–2026
11.3.1. Inactivated Vaccines
11.3.2. Conjugate Vaccines
11.3.3. Live Attenuated Vaccines
11.3.4. Toxoid Vaccines
11.3.5. Other Vaccines
11.4. Market Value Share Analysis, by Animal, 2019–2026
11.5. Market Value Forecast, by Animal, 2018–2026
11.5.1. Livestock Animal Vaccines
11.5.2. Companion Animal Vaccines
11.6. Market Attractiveness Analysis
11.6.1. By Country/Sub-region
11.6.2. By Technology
11.6.3. By Animal
Chapter 12. Latin America Veterinary Vaccines Market Analysis and Forecast
12.1. Market Value Forecast, by Country/Sub-region, 2019–2026
12.1.1. Brazil
12.1.2. Mexico
12.1.3. Rest of Latin America
12.2. Market Value Share Analysis, by Technology, 2019–2026
12.3. Market Value Forecast, by Technology, 2018–2026
12.3.1. Inactivated Vaccines
12.3.2. Conjugate Vaccines
12.3.3. Live Attenuated Vaccines
12.3.4. Toxoid Vaccines
12.3.5. Other Vaccines
12.4. Market Value Share Analysis, by Animal, 2019–2026
12.5. Market Value Forecast, by Animal, 2018–2026
12.5.1. Livestock Animal Vaccines
12.5.2. Companion Animal Vaccines
12.6. Market Attractiveness Analysis
12.6.1. By Country/Sub-region
12.6.2. By Technology
12.6.3. By Animal
Chapter 13. Middle East and Africa Veterinary Vaccines Market Analysis and Forecast
13.1. Market Value Forecast, by Country/Sub-region, 2019–2026
13.1.1. GCC Countries
13.1.2. South Africa
13.1.3. Israel
13.1.4. Rest of Middle East & Africa
13.2. Market Value Share Analysis, by Technology, 2019–2026
13.3. Market Value Forecast, by Technology, 2018–2026
13.3.1. Inactivated Vaccines
13.3.2. Conjugate Vaccines
13.3.3. Live Attenuated Vaccines
13.3.4. Toxoid Vaccines
13.3.5. Other Vaccines
13.4. Market Value Share Analysis, by Animal, 2019–2026
13.5. Market Value Forecast, by Animal, 2018–2026
13.5.1. Livestock Animal Vaccines
13.5.2. Companion Animal Vaccines
13.6. Market Attractiveness Analysis
13.6.1. By Country/Sub-region
13.6.2. By Technology
13.6.3. By Animal
Chapter 14. Competition Landscape
14.1. Competition Matrix
14.1.1. Eli Lilly and Company
14.1.2. Boehringer Ingelheim GmbH
14.1.3. Merck Animal Health
14.1.4. Virbac
14.2. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
14.2.1. Boehringer Ingelheim GmbH (HQ, Business Segments, Employee Strength)
14.2.1.1. Company Details
14.2.1.2. Company Description
14.2.1.3. Business Overview
14.2.1.4. SWOT Analysis
14.2.1.5. Financial Analysis
14.2.1.6. Strategic Overview
14.2.2. Merck Animal Health (HQ, Business Segments, Employee Strength)
14.2.2.1. Company Details
14.2.2.2. Company Description
14.2.2.3. Business Overview
14.2.2.4. SWOT Analysis
14.2.2.5. Strategic Overview
14.2.3. Zoetis Inc. (HQ, Business Segments, Employee Strength)
14.2.3.1. Company Details
14.2.3.2. Company Description
14.2.3.3. Business Overview
14.2.3.4. SWOT Analysis
14.2.3.5. Strategic Overview
14.2.4. Eli Lilly and Company (Elanco Animal Health) (HQ, Business Segments, Employee Strength)
14.2.4.1. Company Details
14.2.4.2. Company Description
14.2.4.3. Business Overview
14.2.4.4. SWOT Analysis
14.2.4.5. Strategic Overview
14.2.5. Bayer AG (HQ, Business Segments, Employee Strength)
14.2.5.1. Company Details
14.2.5.2. Company Description
14.2.5.3. Business Overview
14.2.5.4. SWOT Analysis
14.2.5.5. Financial Analysis
14.2.5.6. Strategic Overview
14.2.6. Ceva Santé Animale. (HQ, Business Segments, Employee Strength)
14.2.6.1. Company Details
14.2.6.2. Company Description
14.2.6.3. Business Overview
14.2.6.4. SWOT Analysis
14.2.6.5. Financial Analysis
14.2.6.6. Strategic Overview
14.2.7. Virbac (HQ, Business Segments, Employee Strength)
14.2.7.1. Company Details
14.2.7.2. Company Description
14.2.7.3. Business Overview
14.2.7.4. SWOT Analysis
14.2.7.5. Financial Analysis
14.2.7.6. Strategic Overview
14.2.8. Biovac (HQ, Business Segments, Employee Strength)
14.2.8.1. Company Details
14.2.8.2. Company Description
14.2.8.3. Business Overview
14.2.8.4. SWOT Analysis
14.2.8.5. Financial Analysis
14.2.8.6. Strategic Overview
14.2.9. Neogen Corporation (HQ, Business Segments, Employee Strength)
14.2.9.1. Company Details
14.2.9.2. Company Description
14.2.9.3. Business Overview
14.2.9.4. SWOT Analysis
14.2.9.5. Strategic Overview
14.2.10. Immucell Corporation (HQ, Business Segments, Employee Strength)
14.2.10.1. Company Details
14.2.10.2. Company Description
14.2.10.3. Business Overview
14.2.10.4. SWOT Analysis
14.2.10.5. Strategic Overview
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers